This article is part of the supplement: Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review
Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review
1 Department of Internal Medicine, University of Cologne, Josef-Stelzmann-Strasse, 50924 Cologne, Germany.
2 Division of Rheumatology, Department of Internal Medicine, University Hospital of Geneva, 26 Avenue Beau-Sejour, 1211 Geneva 14, Switzerland.
Arthritis Research & Therapy 2009, 11(Suppl 1):S1 doi:10.1186/ar2666Published: 6 April 2009
Conventional disease-modifying antirheumatic drugs such as methotrexate are the mainstay of treatment for rheumatoid arthritis. More recently, biologic agents such as etanercept, infliximab and adalimumab, which act by inhibiting tumour necrosis factor (TNF), have become available. TNF inhibitors have proved to be very effective in patients not responding to conventional disease-modifying antirheumatic drugs. However, about 20% to 40% of patients treated with a TNF inhibitor fail to achieve a 20% improvement in American College of Rheumatology criteria, and more lose response over time (secondary failure or acquired therapeutic resistance) or experience adverse events following treatment with a TNF inhibitor. In this group of patients, therapeutic options were limited until recently and an established treatment approach was to switch from one TNF inhibitor to another. In recent years, therapeutic options in these patients have increased with the introduction of biologic agents with novel mechanisms of action, such as rituximab and abatacept. This review outlines the current evidence in support of the available treatment strategies in patients with an inadequate response or intolerance to an initial TNF inhibitor.